Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was ac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Nagot, Nicolas, Singata-Madliki, Mandisa, Cournil, Amandine, Nalugya, Joyce, Tassembedo, Souleymane, Quillet, Catherine, Tonga, Melany W., Tumwine, James, Meda, Nicolas, Kankasa, Chipepo, Mwiya, Mwiya, Bangirana, Paul, Peries, Marianne, Batting, Joanne, Engebretsen, Ingunn M. S., Tylleskär, Thorkild, Perre, Philippe Vande, Ndeezi, Grace, Molès, Jean-Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862474/
https://ncbi.nlm.nih.gov/pubmed/33542437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-82762-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados